Clinical Research Directory
Browse clinical research sites, groups, and studies.
Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney
Sponsor: Trans Tasman Radiation Oncology Group
Summary
This study is evaluating the activity and efficacy of Stereotactic Ablative Body Radiotherapy (SABR) for the treatment of kidney cancers.
Official title: Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney, a Phase II Clinical Trial (FASTRACK II)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
71
Start Date
2016-07
Completion Date
2025-11-24
Last Updated
2026-09-29
Healthy Volunteers
No
Conditions
Interventions
SABR
Renal cell carcinoma (RCC) is conventionally considered "radioresistant" to fully fractionated EBRT. In an effort to overcome the perceived "radioresistance" of RCC, severely hypofractionated External beam radiation therapy (EBRT) in the form of stereotactic radiotherapy will be used in the management of renal cell carcinoma with radiotherapy.
Locations (1)
Peter MacCallum Cancer Centre
East Melbourne, Victoria, Australia